CorMedix to Acquire Melinta Therapeutics for $300 Million, Gaining Seven Commercial Anti-Infective Products

On August 7 (local time), biopharmaceutical company CorMedix Inc. (NASDAQ: CRMD) and novel antibiotic developer Melinta Therapeutics, Inc. (NASDAQ: MLNT) announced that they had entered into a definitive agreement under which CorMedix will acquire Melinta. Under the terms of the agreement, CorMedix will pay Melinta an upfront consideration of $300 million (approximately RMB 2.155 billion), subject to customary adjustments, comprising $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders in the form of pre-funded warrants.

In addition, the agreement includes a potential regulatory milestone payment of $25 million for FDA approval of REZZAYO for the prevention of invasive fungal infections in adults undergoing allogeneic BMT (payable if the milestone is achieved by June 30, 2029). Furthermore, the agreement provides for royalties on net sales of MINOCIN and REZZAYO. The transaction has been approved by the boards of directors of both companies and is expected to close as early as September 2025.

Melinta, founded in 2000 and formerly known as Rib-X Pharmaceuticals, Inc., adopted its current name in October 2013. Headquartered in Connecticut, USA, it is a small commercial-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in both hospital and community settings.

In 2011, Melinta entered into a global research collaboration and license option agreement with Sanofi to develop and commercialize novel antibiotics. Additionally, in recent years, Melinta has executed licensing agreements with institutions and companies such as Yale University, Wakunaga Pharmaceutical, and CyDex Pharmaceuticals.

Currently, the company has a portfolio of seven commercialized products,The portfolio primarily includes antibiotic products such as REZZAYO (rezafungin for injection), MINOCIN (minocycline) for injection, VABOMERE (meropenem-vaborbactam), KIMYRSA (oritavancin), ORBACTIV (oritavancin), and BAXDELA (delafloxacin), as well as another established cardiovascular product, TOPROL-XL (metoprolol succinate).

Among these, the core product REZZAYO has been approved for the treatment of candidemia and invasive candidiasis in adults. At the time of approval, REZZAYO was the first new therapy approved in over a decade for the treatment of candidiasis and invasive candidiasis. Currently, a Phase III study is underway to evaluate its use in preventing invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation (BMT), with completion expected in the first half of 2026.

Leveraging Melinta’s robust product portfolio, the company generated $120 million in revenue in 2024 and is projected to reach $125 million to $135 million in fiscal year 2025.

CorMedix focuses on the development and commercialization of therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The company is prioritizing the commercialization of its core product, DefenCath, in the United States and other major markets. DefenCath (tauridime and heparin) Catheter Lock Solution (CLS) received FDA approval in November 2023 to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with renal failure undergoing long-term hemodialysis via central venous catheters (CVCs). DefenCath is the first antimicrobial CLS approved by the FDA in the United States, having demonstrated up to a 71% reduction in the risk of CRBSIs in a Phase 3 clinical study.

Based on its core product, DefenCath, CorMedix projects its 2025 revenue to be between $180 million and $200 million. With the growth in DefenCath sales and the seven commercialized products acquired through this transaction, CorMedix expects its 2025 revenue to range from $305 million to $335 million.

Compared to the pharmaceutical subsectors of autoimmune diseases, weight loss, and oncology, which frequently make headlines, the anti-infective (infection) market within the pharmaceutical industry remains relatively low-profile and quiet.

However, the reality is that for the vast majority of fatal diseases worldwide, patient deaths are not caused by the progression of the primary disease but rather by infections. For instance, 68.18% of lung cancer patients die directly or indirectly from pulmonary infections. Consequently, the global antibiotic market is substantial. According to relevant data, the global antibiotic market size was approximately $40 billion in 2022 and is projected to reach $50 billion by 2028, with a compound annual growth rate (CAGR) of about 3.5%.

The Chinese market is a vital component of the global antibiotics market, accounting for approximately 20% of the global market size. In recent years, driven by an aging population, heightened health awareness among residents, and expanded medical insurance coverage, China’s antibiotics market has maintained steady growth. In 2023, the market size reached approximately RMB 208 billion, representing a year-on-year increase of RMB 6.637 billion from 2022. The market is dominated by broad-spectrum antibiotics, with the top 10 products easily achieving sales revenues exceeding RMB 1 billion, RMB 2 billion, or even RMB 5 billion.

Currently, in the R&D sector, antibacterial and anti-infective therapies remain a global public health priority, with this field undergoing profound changes and continuous expansion. On one hand, even as the issue of antibiotic misuse improves, bacteria and their resistance patterns continue to evolve. We must constantly innovate and improve current anti-infective drugs, develop new therapies for drug-resistant bacteria, and provide patients with the greatest chance of survival from infections. On the other hand, global investment in antibiotics targeting drug-resistant bacteria with novel mechanisms is limited and progress is slow, while large pharmaceutical companies have shifted their R&D focus to other therapeutic areas. Consequently, the supply-demand imbalance in the treatment of drug-resistant bacterial infections has become more pronounced.

With a disproportionate ratio of input to output, global pharmaceutical giants such as Novartis, AstraZeneca, and Sanofi have abandoned antibiotic research due to profit considerations. However, the WHO predicts that by 2050, up to 10 million people worldwide could die annually from diseases caused by antibiotic-resistant bacteria. Amid the antibiotic crisis, there is an urgent need for the development and launch of new antibiotics.

Driven by urgent clinical needs, numerous companies worldwide have chosen to enter this field. For instance, both domestic and international enterprises—including Kinvard Bio, Basilea Pharmaceutica, Bioversys, Entasis Therapeutics, Paratek Pharmaceuticals, Nabriva Therapeutics, GaoKe Biotech, EverMed, Sinocelltech, and MicuRx Pharmaceuticals—are actively expanding their presence in the novel antibiotics sector.

Overall, despite the challenges of high costs and low market returns in antibiotic R&D, the aforementioned companies continue to advance the development of novel antibiotics through innovative mechanisms, support from governments or non-profit organizations, and international cooperation, so as to address the increasingly severe global problem of antimicrobial resistance.